BMRN - BioMarin Pharmaceutical Inc.
| Previous Close | 87.75 |
| Open | 88.27 |
| Bid | 62.13 x 200 |
| Ask | 91.86 x 100 |
| Day's Range | 85.93 - 88.46 |
| 52 Week Range | 78.42 - 100.51 |
| Volume | 1,460,697 |
| Avg. Volume | 1,325,366 |
| Market Cap | 15.15B |
| Beta | 1.88 |
| PE Ratio (TTM) | -80.50 |
| EPS (TTM) | -1.07 |
| Earnings Date | Oct 26, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 113.27 |
- CNBC Videos•5 days ago
BioMarin is 'close as can get' to a hemophilia cure, CEO ...
Jim Cramer caught up with JJ Bienaime, the chairman and CEO of BioMarin, who spoke to his company's promising pipeline of drugs.
Markit•20 hours agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•23 hours ago
What's in Store for BioMarin (BMRN) This Earnings Season?
BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.
Markit•4 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $931 million.
- Zacks•5 days ago
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
- Capital Cube•5 days ago
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for BioMarin Pharmaceutical, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
- TheStreet.com•5 days ago
BioMarin Pharmaceutical: Cramer's Top Takeaways
JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio.
- Simply Wall St.•6 days ago
Have Investors Already Priced In BioMarin Pharmaceutical Inc’s (BMRN) Growth?
Let’s talk about the popular BioMarin Pharmaceutical Inc (NASDAQ:BMRN). The company’s shares saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS.Read More...
- PR Newswire•6 days ago
BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
SAN RAFAEL, Calif., Oct. 18, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) updated the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.
Markit•6 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•8 days ago
BioMarin Pharmaceutical, Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
What: BioMarin Pharmaceutical, Inc., a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes, will visit the Nasdaq MarketSite in Times ...
- Investor's Business Daily•11 days ago
How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs
Spark's positive vote by an FDA committee could be a boon for other drugmakers working on gene therapies including Audentes, BioMarin and Ultragenyx.
- PR Newswire•13 days ago
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
SAN RAFAEL, Calif. , Oct. 11, 2017 /PRNewswire/ -- Key program updates will include the following: BMN 270 gene therapy for hemophilia A: 4e13 dose and Phase 3 Study Design Vosoritide for achondroplasia: ...
- PR Newswire•14 days ago
BioMarin to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, October 26 at 4:30 p.m. ET
SAN RAFAEL, Calif. , Oct. 10, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...
Markit•15 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $508 million.
- Market Realist•15 days ago
Analysts’ Recommendations for Biogen in October 2017
Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ...
- Market Realist•20 days ago
Alexion on the Street: Analyst Recommendations in October
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
- PR Newswire•21 days ago
BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
SAN RAFAEL, Calif. , Oct. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...
Markit•22 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $15 million.
Markit•25 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN
Markit•26 days agoSee what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRN
- Capital Cube•27 days ago
ETFs with exposure to BioMarin Pharmaceutical, Inc. : September 27, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioMarin Pharmaceutical, Inc. Here are 5 ETFs with the largest exposure to BMRN-US. Comparing the performance and risk of BioMarin Pharmaceutical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Zacks•29 days ago
Here's Why Sarepta Stock is Up More Than 60% So Far in 2017
Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.
- Zacks•last month
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
- Zacks•last month
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.
